FoxHollow and Merck study cardiac biomarkers
FoxHollow Technologies (cardiovascular devices) and Merck have entered into a three-year pharmacogenomics deal to analyze atherosclerotic plaque and identify genes and proteins associated with cardiovascular disease progression.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Technologies
- Includes Contract
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.